Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

NCT02304185 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: gp140, 50 mcg
BIOLOGICAL: gp140, 50 mcg + Adjuvant
BIOLOGICAL: gp140, 250 mcg
BIOLOGICAL: gp140, 250 mcg + Adjuvant
DRUG: Placebo

Sponsor

Crucell Holland BV

Collaborators

[object Object]
[object Object]